Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-975-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.62 million
Profitability
Miscellaneous
Employees79
Next Earnings Date7/30/2019 (Estimated)
OptionableOptionable
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.02. The biotechnology company earned $4.28 million during the quarter, compared to analyst estimates of $3.71 million. Progenics Pharmaceuticals had a negative return on equity of 61.96% and a negative net margin of 436.57%. View Progenics Pharmaceuticals' Earnings History.
When is Progenics Pharmaceuticals' next earnings date?
What price target have analysts set for PGNX?
3 equities research analysts have issued 1 year target prices for Progenics Pharmaceuticals' stock. Their forecasts range from $6.50 to $13.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $10.50 in the next year. This suggests a possible upside of 142.5% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.
What is the consensus analysts' recommendation for Progenics Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.
Has Progenics Pharmaceuticals been receiving favorable news coverage?
News coverage about PGNX stock has been trending somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the near term.
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Innoviva (INVA), Endo International (ENDP), Heron Therapeutics (HRTX), Cambrex (CBM), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Epizyme (EPZM), Turning Point Therapeutics (TPTX), Theravance Biopharma (TBPH) and Eidos Therapeutics (EIDX).
What other stocks do shareholders of Progenics Pharmaceuticals own?
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Mr. Mark R. Baker, CEO & Director (Age 64)
- Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)
- Mr. Benedict Osorio, Chief Operating Officer (Age 62)
- Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
- Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.01%), Eagle Asset Management Inc. (5.33%), Rice Hall James & Associates LLC (2.71%), Pinnacle Associates Ltd. (1.68%), Royce & Associates LP (1.42%) and Phocas Financial Corp. (1.36%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which major investors are selling Progenics Pharmaceuticals stock?
PGNX stock was sold by a variety of institutional investors in the last quarter, including Phocas Financial Corp., Royce & Associates LP, JPMorgan Chase & Co., Parametric Portfolio Associates LLC, New York State Common Retirement Fund, Pinnacle Associates Ltd., SEI Investments Co and BlueMountain Capital Management LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.
Which major investors are buying Progenics Pharmaceuticals stock?
PGNX stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Wells Fargo & Company MN, Rice Hall James & Associates LLC, Morgan Stanley, Geode Capital Management LLC, Charles Schwab Investment Management Inc. and SG Americas Securities LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $4.33.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $366.06 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.
What is Progenics Pharmaceuticals' official website?
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
